1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Praxis Aims To Complete ET Trial Despite Likely Primary Endpoint Miss

 
• By Alaric DeArment

The Essential3 program’s data monitoring committee recommended stopping one of the essential tremor studies for futility, but the company said it will continue the trials anyway.

tremor
• Source: Shutterstock
Key Takeaways
  • The Essential3 program’s data monitoring committee said Study 1 is unlikely to meet its primary endpoint and recommended stopping the trial for futility.
  • Praxis plans to complete the study anyway given how far along enrollment in Study 1 and Study 2 has come.
  • The company also reported its fourth quarter and full-year 2024 financials, reporting an uptick in cash that it said would fund operations into 2028.

Praxis Precision Medicines is not giving up on ulixacaltamide in essential tremor (ET) after the independent data monitoring committee (IDMC) for the Phase III Essential3 program said one of the...

The Boston-based neurology-focused biotech said 28 February that Essential3’s IDMC issued the recommendation for Study 1 based on an interim analysis. However, Praxis plans to continue both Study 1 and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

More from Scrip

Genentech, Orionis Stick Together In Second Molecular Glue Deal

 
• By Alaric DeArment

Deal Snapshot: Orionis and Genentech signed a new partnership focused on molecular glues, on top of the one that they struck in 2023.

Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts

 
• By Mandy Jackson

Restructuring Edition: Prime Medicine ended its sole clinical-stage program to prioritize preclinical and partnered programs, cutting 25% of its workforce to extend its cash runway. Meanwhile, earnings season brought workforce reductions at Kyverna, Allogene, Leap and others.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.